PLYX Polaryx Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2075320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-114.9%
ROA-101.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.6%
Debt / equity0.00x
Current ratio8.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | — | — | — | — |
| R&D expense | $2.45M | $719,000 | $679,000 | $560,000 | $514,000 | $476,000 | $4.72M |
| SG&A expense | $877,000 | $661,000 | $1.28M | $351,000 | $460,000 | $408,000 | $336,000 |
| Operating income | -$3.33M | -$1.38M | -$1.96M | -$911,000 | -$974,000 | -$884,000 | -$5.05M |
| Net income | -$3.33M | -$1.38M | -$2.54M | -$1.50M | -$1.43M | -$1.01M | -$5.05M |
| EPS (basic) | -0.07 | -0.03 | -0.05 | — | -0.03 | -0.02 | -0.11 |
| EPS (diluted) | -0.07 | -0.03 | -0.05 | — | -0.03 | -0.02 | -0.11 |
| Weighted avg. shares (diluted) | 49.85M | 48.28M | 47.22M | — | 45.79M | 44.67M | 44.34M |
| Balance sheet | |||||||
| Cash & equivalents | $8.44M | $11.54M | $3.08M | $5.14M | — | — | — |
| Current assets | $8.61M | $11.81M | $3.50M | $5.17M | — | — | — |
| Total assets | $8.61M | $11.81M | $3.50M | $5.17M | — | — | — |
| Current liabilities | $999,000 | $873,000 | $1.01M | $605,000 | — | — | — |
| Total liabilities | $999,000 | $873,000 | $1.01M | $605,000 | — | — | — |
| Shareholders' equity | $7.61M | $10.94M | $2.49M | $4.57M | $5.30M | $3.25M | $4.25M |
| Shares outstanding | 49.85M | 49.85M | 47.34M | 47.34M | — | — | — |
| Cash flow statement | |||||||
| Operating cash flow | -$3.10M | -$1.37M | -$2.06M | -$1.49M | -$887,000 | -$858,000 | -$709,000 |
| Financing cash flow | $0 | — | — | $888,000 | $3.33M | $0 | $250,000 |
| Stock-based compensation | $0 | $0 | $467,000 | $57,000 | $108,000 | $109,000 | $4.45M |
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.